{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:06:24Z","timestamp":1762099584801,"version":"build-2065373602"},"reference-count":43,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.5551\/jat.64528","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T22:11:26Z","timestamp":1707171086000},"page":"1087-1097","source":"Crossref","is-referenced-by-count":2,"title":["Anti-Lipoprotein Lipase Antibody as a Useful Marker for Plaque Vulnerability in Patients with Stable Angina"],"prefix":"10.5551","volume":"31","author":[{"given":"Miyu","family":"Yoshinaga","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eika","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hyogo Prefectural Nishinomiya Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Gaggini M, Gorini F and Vassalle C: Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. Int J Mol Sci, 2022; 24:","DOI":"10.3390\/ijms24010075"},{"key":"2","unstructured":"2) Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, Doran AC and Vickers KC: The Role of Lipids and Lipoproteins in Atherosclerosis. In: Endotext, ed by Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, and Wilson DP, South Dartmouth (MA), 2000"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Herrington W, Lacey B, Sherliker P, Armitage J and Lewington S: Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res, 2016; 118: 535-546","DOI":"10.1161\/CIRCRESAHA.115.307611"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, Fowkes FGR, Fowkes FJI and Rudan I: Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health, 2020; 8: e721-e729","DOI":"10.1016\/S2214-109X(20)30117-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J and investigators A: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Officers A, Coordinators for the ACRGTA and Lipid-Lowering Treatment to Prevent Heart Attack T: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002; 288: 2998-3007","DOI":"10.1001\/jama.288.23.2998"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG and Risk PsgPSoPitEa: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-1630","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Heart Protection Study Collaborative G: MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Long-Term Intervention with Pravastatin in Ischaemic Disease Study G: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357","DOI":"10.1056\/NEJM199811053391902"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W and Gotto AM, Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998; 279: 1615-1622","DOI":"10.1001\/jama.279.20.1615"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH and Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307","DOI":"10.1056\/NEJM199511163332001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR and Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009","DOI":"10.1056\/NEJM199610033351401"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Group SSSS: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology T, Prevention Committee of the Council on Nutrition PA, Metabolism, Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular N and Council on the Kidney in Cardiovascular D: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nordestgaard BG, Benn M, Schnohr P and Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299-308","DOI":"10.1001\/jama.298.3.299"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Sandesara PB, Virani SS, Fazio S and Shapiro MD: The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev, 2019; 40: 537-557","DOI":"10.1210\/er.2018-00184"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF and European Atherosclerosis Society Consensus P: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361","DOI":"10.1016\/S1567-5688(11)70033-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bjorkbacka H, Alm R, Persson M, Hedblad B, Nilsson J and Fredrikson GN: Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events. Arterioscler Thromb Vasc Biol, 2016; 36: 765-771","DOI":"10.1161\/ATVBAHA.115.306938"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK and Nilsson J: Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis, 2007; 194: e188-192","DOI":"10.1016\/j.atherosclerosis.2006.12.014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sjogren P, Fredrikson GN, Samnegard A, Ericsson CG, Ohrvik J, Fisher RM, Nilsson J and Hamsten A: High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J, 2008; 29: 2218-2226","DOI":"10.1093\/eurheartj\/ehn336"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Asciutto G, Dias NV, Edsfeldt A, Alm R, Fredrikson GN, Goncalves I and Nilsson J: Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy. Atherosclerosis, 2015; 239: 289-294","DOI":"10.1016\/j.atherosclerosis.2015.01.023"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Fredrikson GN, Anand DV, Hopkins D, Corder R, Alm R, Bengtsson E, Shah PK, Lahiri A and Nilsson J: Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia, 2009; 52: 1426-1433","DOI":"10.1007\/s00125-009-1377-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) McLeod O, Silveira A, Fredrikson GN, Gertow K, Baldassarre D, Veglia F, Sennblad B, Strawbridge RJ, Larsson M, Leander K, Gigante B, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Humphries SE, Tremoli E, de Faire U, Ohrvik J, Nilsson J and Hamsten A: Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis, 2014; 232: 242-248","DOI":"10.1016\/j.atherosclerosis.2013.11.041"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Imai M, Kawamura M, Kochi I, Matsuoka T, Kihara S and Yamamoto H: Anti-Apo B-100 Autoantibody is a Marker of Unstable Coronary Plaque. Journal of atherosclerosis and thrombosis, 2021; 28: 1025-1034","DOI":"10.5551\/jat.58784"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yamamoto H, Kawamura M, Kochi I, Imai M, Murata Y, Suzuki T, Chen Y, Hashimoto K and Kihara S: Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment. Journal of atherosclerosis and thrombosis, 2019; 26: 931-943","DOI":"10.5551\/jat.46797"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kihara S, Matsuzawa Y, Kubo M, Nozaki S, Funahashi T, Yamashita S, Sho N and Tarui S: Autoimmune hyperchylomicronemia. N Engl J Med, 1989; 320: 1255-1259","DOI":"10.1056\/NEJM198905113201906"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Yamamoto H, Tanaka M, Yoshiga S, Funahashi T, Shimomura I and Kihara S: Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody. J Clin Endocrinol Metab, 2014; 99: 1525-1530","DOI":"10.1210\/jc.2013-3619"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charriere S, Fong LG, Nakajima K and Young SG: Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. N Engl J Med, 2017; 376: 1647-1658","DOI":"10.1056\/NEJMoa1611930"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Rodrigues CE, Bonf\u00e1 E and Carvalho JF: Review on anti-lipoprotein lipase antibodies. Clin Chim Acta, 2010; 411: 1603-1605","DOI":"10.1016\/j.cca.2010.07.028"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Reichlin M, Fesmire J, Quintero-Del-Rio AI and Wolfson-Reichlin M: Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum, 2002; 46: 2957-2963","DOI":"10.1002\/art.10624"},{"key":"31","unstructured":"31) Kodera M, Hayakawa I, Komura K, Yanaba K, Hasegawa M, Takehara K and Sato S: Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. J Rheumatol, 2005; 32: 629-636"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP and Bonf\u00e1 E: Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum, 2004; 50: 3610-3615","DOI":"10.1002\/art.20630"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Matsuo N, Matsuoka T, Onishi S, Yamamoto H, Kato A, Makino Y and Kihara S: Impact of Remnant Lipoprotein on Coronary Plaque Components. Journal of atherosclerosis and thrombosis, 2015; 22: 783-795","DOI":"10.5551\/jat.26328"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Chang SF, Reich B, Brunzell JD and Will H: Detailed characterization of the binding site of the lipoprotein lipase-specific monoclonal antibody 5D2. J Lipid Res, 1998; 39: 2350-2359","DOI":"10.1016\/S0022-2275(20)33314-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Luz JG, Beigneux AP, Asamoto DK, He C, Song W, Allan CM, Morales J, Tu Y, Kwok A, Cottle T, Meiyappan M, Fong LG, Kim JE, Ploug M, Young SG and Birrane G: The structural basis for monoclonal antibody 5D2 binding to the tryptophan-rich loop of lipoprotein lipase. J Lipid Res, 2020; 61: 1347-1359","DOI":"10.1194\/jlr.RA120000993"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kawashiri MA, Higashikata T, Mizuno M, Takata M, Katsuda S, Miwa K, Nozue T, Nohara A, Inazu A, Kobayashi J, Koizumi J and Mabuchi H: Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis. J Clin Endocrinol Metab, 2005; 90: 6541-6544","DOI":"10.1210\/jc.2005-1098"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Ebara T, Endo Y, Yoshiike S, Tsuji M, Taguchi S, Murase T and Okubo M: A 60-y-old chylomicronemia patient homozygous for missense mutation (G188E) in the lipoprotein lipase gene showed no accelerated atherosclerosis. Clin Chim Acta, 2007; 386: 100-104","DOI":"10.1016\/j.cca.2007.08.011"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Ebara T, Okubo M, Horinishi A, Adachi M, Murase T and Hirano T: No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61--\uff1estop) in the lipoprotein lipase gene. Atherosclerosis, 2001; 159: 375-379","DOI":"10.1016\/S0021-9150(01)00510-X"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagne E, Hayden MR and Kastelein JJ: The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation, 1996; 94: 1913-1918","DOI":"10.1161\/01.CIR.94.8.1913"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G and Tybjaerg-Hansen A: Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation, 1997; 96: 1737-1744","DOI":"10.1161\/01.CIR.96.6.1737"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) de Carvalho JF, Bonfa E and Borba EF: Systemic lupus erythematosus and \u201clupus dyslipoproteinemia\u201d. Autoimmun Rev, 2008; 7: 246-250","DOI":"10.1016\/j.autrev.2007.11.016"},{"key":"42","unstructured":"42) de Carvalho JF, Viana VS, Neto EF, Santos RD and Bonf\u00e1 E: Anti-lipoprotein lipase antibodies in patients with hypertriglyceridemia without associated autoimmune disease. Isr Med Assoc J, 2011; 13: 350-353"},{"key":"43","unstructured":"43) Zeng Z, Cao B, Guo X, Li W, Li S, Chen J, Zhou W, Zheng C and Wei Y: Apolipoprotein B-100 peptide 210 antibody inhibits atherosclerosis by regulation of macrophages that phagocytize oxidized lipid. Am J Transl Res, 2018; 10: 1817-1828"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/7\/31_64528\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T04:35:15Z","timestamp":1720240515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/7\/31_64528\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.64528","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"type":"print","value":"1340-3478"},{"type":"electronic","value":"1880-3873"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"64528"}}